The U.S. Food and Drug Administration (FDA) has approved Allergan’s Rhofade cream for the topical treatment of persistent facial erythema (redness) associated with rosacea in adults. The National Rosacea Society (NRS) estimates that approximately 16 million Americans are affected by rosacea, yet effective treatment has been limited. “Historically, there haven’t been many options available to help physicians address persistent facial erythema and often we ended up just helping our patients identify and manage triggers, which can lead to frustration for both the doctor and patient,” says Robert Weiss, M.D., clinical trial investigator and director of Maryland Laser, Skin & Vein Institute (Baltimore). “With the approval of Rhofade, doctors will now be able to provide their patients with an effective once-daily treatment option to help manage this condition.”